These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 31658140)

  • 1. Interaction of CYP2C19 G681A polymorphism and omeprazole on clopidogrel responsiveness and impact in patients with acute coronary syndrome.
    Jirungda S; Pussadhamma B; Komanasin N; Senthong V; Leuangwatthananon W
    Coron Artery Dis; 2020 May; 31(3):266-272. PubMed ID: 31658140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetic testing by polymorphic markers 681G>A and 636G>A CYP2C19 gene in patients with acute coronary syndrome and gastric ulcer in the Republic of Sakha (Yakutia).
    Fedorinov DS; Mirzaev KB; Ivashchenko DV; Temirbulatov II; Sychev DA; Maksimova NR; Chertovskih JV; Popova NV; Tayurskaya KS; Rudykh ZA
    Drug Metab Pers Ther; 2018 Jun; 33(2):91-98. PubMed ID: 29738309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The effects of cytochrome P450 2C19 genetic polymorphism on clopidogrel resistance and recent prognosis of patients with acute coronary syndrome].
    Li SN; Liu Z; Luo Y; Chen PA; Lei XM; Li GL
    Zhonghua Nei Ke Za Zhi; 2013 Nov; 52(11):961-5. PubMed ID: 24439192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genotype-Phenotype Association and Impact on Outcomes following Guided De-Escalation of Anti-Platelet Treatment in Acute Coronary Syndrome Patients: The TROPICAL-ACS Genotyping Substudy.
    Gross L; Trenk D; Jacobshagen C; Krieg A; Gawaz M; Massberg S; Baylacher M; Aradi D; Stimpfle F; Hromek J; Vogelgesang A; Hadamitzky M; Sibbing D; Geisler T
    Thromb Haemost; 2018 Sep; 118(9):1656-1667. PubMed ID: 30103241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clustering of ABCB1 and CYP2C19 Genetic Variants Predicts Risk of Major Bleeding and Thrombotic Events in Elderly Patients with Acute Coronary Syndrome Receiving Dual Antiplatelet Therapy with Aspirin and Clopidogrel.
    Galeazzi R; Olivieri F; Spazzafumo L; Rose G; Montesanto A; Giovagnetti S; Cecchini S; Malatesta G; Di Pillo R; Antonicelli R
    Drugs Aging; 2018 Jul; 35(7):649-656. PubMed ID: 29936693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction between platelet-derived microRNAs and CYP2C19*2 genotype on clopidogrel antiplatelet responsiveness in patients with ACS.
    Peng L; Liu J; Qin L; Liu J; Xi S; Lu C; Yin T
    Thromb Res; 2017 Sep; 157():97-102. PubMed ID: 28734158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular outcomes associated with concomitant use of clopidogrel and proton pump inhibitors in patients with acute coronary syndrome in Taiwan.
    Lin CF; Shen LJ; Wu FL; Bai CH; Gau CS
    Br J Clin Pharmacol; 2012 Nov; 74(5):824-34. PubMed ID: 22364155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of the proton pump inhibitors and CYP2C19*2 polymorphism on platelet response to clopidogrel as assessed by four platelet function assays.
    Tsantes AE; Ikonomidis I; Papadakis I; Bonovas S; Gialeraki A; Kottaridi C; Kyriakou E; Kokori S; Douramani P; Kopterides P; Karakitsos P; Lekakis J; Kapsimali V
    Thromb Res; 2013 Aug; 132(2):e105-11. PubMed ID: 23830212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytochrome P450 CYP 2C19*2 Associated with Adverse 1-Year Cardiovascular Events in Patients with Acute Coronary Syndrome.
    Wei YQ; Wang DG; Yang H; Cao H
    PLoS One; 2015; 10(7):e0132561. PubMed ID: 26147597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the effect of CYP2C19 polymorphism on clinical outcome between acute coronary syndrome and stable angina.
    Arima Y; Hokimoto S; Akasaka T; Mizobe K; Kaikita K; Oniki K; Nakagawa K; Ogawa H
    J Cardiol; 2015 Jun; 65(6):494-500. PubMed ID: 25156215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between cytochrome P450 2C19 polymorphism and clinical outcomes in clopidogrel-treated Uygur population with acute coronary syndrome: a retrospective study.
    Yu L; Wang T; Bai H; Zhu W; Li Y; Wu J; Liu W; Sun L; Yu A; Li H
    BMC Cardiovasc Disord; 2021 Aug; 21(1):391. PubMed ID: 34384383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Impact of proton pump inhibitor omeprazole on the antiplatelet effect of clopidogrel in individuals with various CYP2C19*2 genotypes].
    Lu FM; Tong ZL; Mao YM; Wu DY; Xu J
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2012 Aug; 29(4):478-81. PubMed ID: 22875511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clopidogrel utilization in patients with coronary artery disease and diabetes mellitus: should we determine CYP2C19*2 genotype?
    Chouchene S; Dabboubi R; Raddaoui H; Abroug H; Ben Hamda K; Hadj Fredj S; Abderrazak F; Gaaloul M; Rezek M; Neffeti F; Hellara I; Sassi M; Khefacha L; Sriha A; Nouira S; Najjar MF; Maatouk F; Messaoud T; Hassine M
    Eur J Clin Pharmacol; 2018 Dec; 74(12):1567-1574. PubMed ID: 30073432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of CYP2C19 Metabolizer Status on Patients With ACS Treated With Prasugrel Versus Clopidogrel.
    Doll JA; Neely ML; Roe MT; Armstrong PW; White HD; Prabhakaran D; Winters KJ; Duvvuru S; Sundseth SS; Jakubowski JA; Gurbel PA; Bhatt DL; Ohman EM; Fox KAA;
    J Am Coll Cardiol; 2016 Mar; 67(8):936-947. PubMed ID: 26916483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in CYP2C19 enzyme activity evaluated by the [(13)C]-pantoprazole breath test after co-administration of clopidogrel and proton pump inhibitors following percutaneous coronary intervention and correlation to platelet reactivity.
    Harvey A; Modak A; Déry U; Roy M; Rinfret S; Bertrand OF; Larose É; Rodés-Cabau J; Barbeau G; Gleeton O; Nguyen CM; Proulx G; Noël B; Roy L; Paradis JM; De Larochellière R; Déry JP
    J Breath Res; 2016 Jan; 10(1):017104. PubMed ID: 26815196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic Evaluations of CYP2C19 Genotype-Guided Antiplatelet Therapy Compared to the Universal Use of Antiplatelets in Patients With Acute Coronary Syndrome: A Systematic Review.
    AlMukdad S; Elewa H; Al-Badriyeh D
    J Cardiovasc Pharmacol Ther; 2020 May; 25(3):201-211. PubMed ID: 32027168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Relationship between ATP-binding cassette subfamily B member 1 and cytochrome P450 2C19 polymorphisms and the effect of clopidogrel post percutaneous coronary intervention in patients with acute coronary syndrome].
    Zhou CF; Ren YH; Song YQ; Yi J; Han BS; Xue Q; Fu ZH; Li DY
    Zhonghua Xin Xue Guan Bing Za Zhi; 2016 Apr; 44(4):309-14. PubMed ID: 27112608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of CYP2C19 Polymorphism with Clopidogrel Resistance in Patients with Acute Coronary Syndrome in China.
    Su Q; Li J; Tang Z; Yang S; Xing G; Liu T; Peng H
    Med Sci Monit; 2019 Sep; 25():7138-7148. PubMed ID: 31543510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of coexisting polymorphisms of CYP2C19 and P2Y12 on clopidogrel responsiveness and clinical outcome in patients with acute coronary syndromes undergoing stent-based coronary intervention.
    Tang XF; Zhang JH; Wang J; Han YL; Xu B; Qiao SB; Wu YJ; Chen J; Wu Y; Chen JL; Gao RL; Yang YJ; Yuan JQ
    Chin Med J (Engl); 2013 Mar; 126(6):1069-75. PubMed ID: 23506580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between cardiovascular outcomes and proton pump inhibitor use in patients receiving dual antiplatelet therapy after acute coronary syndrome.
    Hsiao FY; Mullins CD; Wen YW; Huang WF; Chen PF; Tsai YW
    Pharmacoepidemiol Drug Saf; 2011 Oct; 20(10):1043-9. PubMed ID: 21823195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.